Strategies of AI ‐Driven CAR ‐T Cell Therapy Towards Solid Tumours
- 19 February 2026
- journal article
- review article
- Published by Wiley in Immunology
- Vol. 178 (3) , 387-400
Abstract
Chimeric antigen receptor (CAR)‐T cell immunotherapy shows significant success in hematologic malignancies. However, it faces critical challenges in solid tumours, such as suppressive tumour microenvironment (TME) and antigenic heterogeneity, highlighting the urgent need for effective and safe CAR products. The integration of artificial intelligence (AI) into CAR‐T cell immunotherapy offers exceptional opportunities to improve its therapeutic efficacy. More specifically, this paper highlights the transformative role of AI in addressing key challenges that impede the success of CAR‐T cell therapy in solid tumours, including assisting in CAR design and manufacturing process, identifying novel CAR‐targeted genes, and detecting cell heterogeneity in solid tumours. We remain optimistic about AI‐driven strategies for enhancing CAR T‐cell persistence, trafficking, and visualisation in the TME. In addition, we highlight the current challenges and prospects for advancing AI‐driven CAR‐T cell therapies.Keywords
This publication has 136 references indexed in Scilit:
- Artificial Intelligence and the Evolving Landscape of ImmunopeptidomicsProteomics – Clinical Applications, 2025
- From Multi‐Omics to Visualization and Beyond: Bridging Micro and Macro Insights in CAR‐T Cell TherapyAdvanced Science, 2025
- CTHRC1 expresses in cancer-associated fibroblasts and is associated with resistance to anti-androgen therapy in prostate cancerGenes & Genomics, 2025
- Cellular and molecular imaging of CAR-T cell-based immunotherapyAdvanced Drug Delivery Reviews, 2023
- BiTE‐Secreting CAR‐γδT as a Dual Targeting Strategy for the Treatment of Solid TumorsAdvanced Science, 2023
- Magnetic–Acoustic Sequentially Actuated CAR T Cell Microrobots for Precision Navigation and In Situ Antitumor ImmunoactivationAdvanced Materials, 2023
- Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy TreatmentsCurrent Hematologic Malignancy Reports, 2021
- CXCR2‐modified CAR‐T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinomaEuropean Journal of Immunology, 2020
- Generation of CAR-T Cells for Cancer Immunotherapy2018
- Identifying neoantigens for use in immunotherapyMammalian Genome, 2018